Chiasma

    [td_text_with_title custom_title=”Company description”]Chiasma is a biopharmaceutical company focused on evolving orphan medications to better meet the needs of patients and healthcare professionals. Our first priority is the development and commercialization of octreotide capsules – the only oral somatostatin analog. This means the chance to avoid painful needles and minimize symptoms that can arise as traditional injections wear off. It’s a new way of addressing treatment that’s providing a real sense of hope.[/td_text_with_title]
    [td_text_with_title custom_title=”Latest post”]
    Chiasma_ipo

    Chiasma ups IPO price

    Chiasma, a biotech developing oral therapies for orphan diseases only treated by injections, raised $102 million by offering 6.4 million shares (100% primary) at $16, above the $13-$15 range. Chiasma sold 1.0 million more shares than originally planned. At 16 dollar Chisma will have a mcap of $450 million.

    0 comments
    Chiasma_ipo

    Chiasma midpoint value $375 MUSD

    Chiasma, a late-stage biotech developing an oral drug candidate for acromegaly, plans to raise $75 million by offering 5.36 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Chiasma would trade at a market value of $375 million.

    0 comments
    Chiasma_ipo

    Chiasma files NDA for octreotide capsules

    Chiasma, Inc., a U.S. privately held biopharma company, today announced the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of octreotide capsules, an investigational drug for the maintenance treatment of adults with acromegaly. The FDA has a 60-day filing review […]

    0 comments
    Chiasma_ipo

    Acromegaly biotech Chiasma files for a $86 million IPO

    The Newton, MA-based company, which was founded in 2001 and booked $9 million in sales for the 12 months ended March 31, 2015, plans to list on the NASDAQ under the symbol CHMA. Chiasma initially filed confidentially on 4/17/2015. Barclays and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.

    0 comments
    [/td_text_with_title]